Clinical trials: Thrombotic Microangiopathies
Immune Thrombocytopenia
Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura
Current first line treatments for immune thrombocytopenia (ITP) usually have transient effects and prolonged platelet response rate off therapy remains low.
- Trial name
- NCT03830749
- Testing
- Eltrombopag
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Humanity & Health Medical Group Limited
Immune Thrombocytopenia
Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia
The project was undertaking by Qilu Hospital of Shandong University in China. The objective is to find out if there is a connection between vitamin D level and the efficacy of dexamethasone for the treatment of adults with…
- Trial name
- NCT04320225
- Testing
- Dexamethasone
- Volunteers
- 60 people
- Sponsor
- Shandong University
Immune Thrombocytopenia (ITP)
Rituximab as Second Line Treatment for ITP
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized thrombocytopenia. Splenectomy is the standard treatment for patients who fails the first-line treatment: corticosteroid.
- Trial name
- NCT00344149
- Testing
- Rituximab (Mabthera)
- Where
- Norway
- Volunteers
- 112 people
- Sponsor
- Ostfold Hospital Trust
Immune Thrombocytopenia
The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune…
- Trial name
- ITP (NCT03201848)
- Testing
- Huaiqihuang Granule
- Where
- 14 sites in China
- Volunteers
- 216 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Idiopathic Thrombocytopenic Purpura
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05492409
- Testing
- GNR-069
- Where
- 13 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM
Transplant-Associated Thrombotic Microangiopathy
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
- Trial name
- NCT05148299
- Testing
- Pegcetacoplan
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 12 people
- Sponsor
- Swedish Orphan Biovitrum
Immune Thrombocytopenia
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10^9/L in the…
- Trial name
- NCT02279173
- Testing
- Romiplostim
- Where
- 78 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- Amgen
Atypical Hemolytic-Uremic Syndrome
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and…
- Trial name
- NCT01194973
- Testing
- Eculizumab
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 44 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Idiopathic Thrombocytopenic Purpura
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study.
- Trial name
- PETIT2 (NCT01520909)
- Testing
- Eltrombopag
- Where
- 51 sites in United States, Argentina and 11 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.
- Trial name
- NCT05086744
- Testing
- Iptacopan
- Where
- 8 sites in United States, Germany and 4 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenic Purpura (ITP)
Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by antibody-mediated platelet destruction. The complex pathogenesis of ITP with multiple challenges to immune system in terms of genetic…
- Trial name
- NCT02877212
- Testing
- Eltrombopag
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Immune Thrombocytopenia
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
The project was undertaking by Qilu Hospital, Shandong University and other several well-known hospitals in China. In order to report the efficacy and safety of Rituximab in different frequencies for the treatment of adults with…
- Trial name
- NCT02137681
- Testing
- Rituximab
- Where
- China
- Sponsor
- Shandong University
Purpura, Thrombocytopaenic, Idiopathic
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
This study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (Part A and Part B) examining 30, 50, and 75 mg doses of SB-497115-GR as a treatment for patients with ITP…
- Trial name
- NCT00102739
- Testing
- SB497115
- Where
- 30 sites in Germany, Greece and 11 more
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline
Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
This project aims to identify, through RNA-Seq technology, the genetic alterations underlying undiagnosed rare diseases in pediatric and adult patients with early onset and with negative WES.
- Conditions
- Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney, Healthy
- Trial name
- ANTHEM (NCT05996731)
- Testing
- Skin biopsy
- Where
- Italy
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome
- Trial name
- ET-902-AID01 (NCT07212322)
- Testing
- CD19 UCAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune…
- Trial name
- NCT06594146
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Keymed Biosciences Co.Ltd
Immune Thrombocytopenia
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect.
- Trial name
- NCT03229746
- Testing
- Hydroxychloroquine, vincristine, azathioprine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati